Close menu




July 13th, 2021 | 07:55 CEST

BioNTech, Defence Therapeutics, Formycon - Which biotech stock suits which investor?

  • Biotechnology
Photo credits: pixabay.com

Corona is and remains the threat of the hour. In this respect, it is not surprising that the papers of the German vaccine pioneer BioNTech have gone on a fabulous journey. Other companies are still trying to jump on this bandwagon, too. For example, both Canada's Defence Therapeutics and Munich-based Formycon AG are researching a Covid-19 vaccine. However, these developments are at very different stages. In addition, the further product spectrum differs significantly in some cases. But which share is the right one for the portfolio? We took a closer look at the three dissimilar siblings.

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , FORMYCON AG | DE000A1EWVY8

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNTech SE - Application to FDA for approval of a third "booster vaccine" likely to expand revenues further

    The positive newsflow at BioNTech does not stop. Protection of the human body after vaccination has proven to be highly robust, even against the various mutations up to the Delta variant of the SARS-CoV-2 virus. However, the Company has now conceded that the protective effect will likely diminish after about half a year. Data from the Israeli Ministry of Health had indicated this. However, what initially sounds like a negative headline opens up great business potential on the other side. According to the Company, vaccination protection can be restored or even improved by a third booster shot.

    Consequently, the Company, together with technology partner Pfizer, has applied to the US Food & Drug Administration (FDA) for approval of the booster shot. Inquiries with the European Medicines Agency (EMA) and other relevant agencies worldwide are expected to follow. In a joint statement with the US Food and Drug Administration (CDC), the FDA initially rejected the third dose for Americans who had previously been fully vaccinated. However, the FDA made it clear that the issue was currently being investigated, and this recommendation could, of course, be revised at any time in the event of new findings.

    According to BioNTech/Pfizer, this will happen soon, so production of the additional vaccine doses could begin very soon. In this context, they also plan to develop a version of the common mRNA vaccine that is better adapted to the new mutations. All of this is fantastic news for existing BioNTech shareholders. Investors who have not yet invested may prefer to pause. Analysts have set their price target at around EUR 150, which would be an upside potential of around 20%.

    Defence Therapeutics - Canadian ADC pioneers report success in the fight against Covid-19

    The Canadian biotechnology Company Defence Therapeutics is developing the next generation of vaccines and ADC preparations (ADC = Antibody Drug Conjugates, i.e. the antibody-drug combination in a "piggyback" process) based on its proprietary Accum platform. This process, which is considered particularly promising for cancer therapy, is similar to the mRNA process used by BioNTech in its Covid-19 vaccine. Defence is also currently researching such a process. A few days ago, the Company announced a great success: serum isolated from animals vaccinated with the AccuVAC-PT001 vaccine developed by Defence showed cross-reactions with the spike protein of several SARS-CoV-2 variants in laboratory tests.

    The highest efficacy was observed with the currently rampant Delta variant. The vaccine was effective in blocking infection of the parent strain. Further laboratory tests are now underway to verify the neutralization ability of the antibodies produced. The long-term goal is to develop a booster vaccine that blocks both virus transmission and immune evasion by means of further mutation. But Defence Therapeutics is also continuing full steam ahead in other areas. A few days ago, the Company informed the public that it had signed a cooperation agreement with the renowned Institut Curie in Paris to test the breast cancer treatment T-DM1 Kadcyla ("Accum-T-DM1-ADC"), which has been optimized using Accum technology. Extensive studies in animal experiments with mice are to be developed.

    Using Accum technology, Defence Therapeutics expects to shorten treatment duration with fewer side effects while increasing efficacy through targeted drug positioning. We regard both announcements as highly positive. According to the market research institute Kuick, the market for breast cancer therapies alone is expected to reach a volume of USD 20 billion by 2026. In addition, there is great potential in the area of Covid-19 fighting. However, Defence Therapeutics is still in the relatively early stages of development with its products. It remains exciting in any case.

    Formycon - Despite good business figures and a positive news flow, the share is currently unable to break out to the upside

    The share price of biosimilar pioneer Formycon seems to be tied to the EUR 60 mark with a rubber band. About a week ago, the Company published quite good financial figures in line with expectations, announced a renewed application for approval of its drug FYB201 and announced that it had found appropriate distribution partners in Teva Pharmaceuticals and Coherus. In addition, the Company announced that its previously unpartnered Covid-19 vaccine FYB207, which is based on a long-acting ACE2 immunoglobulin fusion protein, has received a EUR 12.7 million financial injection from the Free State of Bavaria as part of the "BayTherapie 2020" initiative. Development of the previously unpublished and unpartnered biosimilar candidate FY206 continues as planned. Based on all this data, analysts arrive at an average price target of around EUR 70. In their last update from the beginning of the month, the analysts from First Berlin even see EUR 78 as realistic. However, all this seems to make little impression on the stock market at present. Despite the positive news flow, there is currently no sign of an upward breakout.


    So which biotech stock suits which type of investor? BioNTech's stock is already quite expensive, but we do not expect any slowdown in business in the near future. An investment in Defence Therapeutics is certainly riskier, but in the event of success, high returns await. Equally interesting for us is Formycon. It is unclear why the share price is currently stuck at EUR 60, and the positive newsflow should allow the share price to move upwards soon.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Stefan Feulner on April 16th, 2024 | 07:40 CEST

    Formycon, Defence Therapeutics, Morphosys - Significant movement in the biotech sector

    • Biotechnology
    • Pharma
    • Cancer

    At the moment, investors are focusing on gold and Bitcoin in addition to the most important indices, like the DAX and Dow Jones. Meanwhile, the biotechnology sector is barely mentioned in the local newspapers. However, the market is on the move, and the wave of takeovers continues unabated. Recently, the Danish pharmaceutical company Genmab announced it was acquiring the private biotech company ProfoundBio for USD 1.8 billion in cash. The acquisition is intended to help deepen the cancer pipeline with next-generation antibody-drug conjugate therapies. Big Pharma is likely to make further acquisitions in this area in the near future.

    Read

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

    Read

    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.

    Read